244 results about "Animal study" patented technology

A heart valve sewing prosthesis including an intrinsically conductive polymer. The invention includes annuloplasty rings and bands, and sewing rings or cuffs for prosthetic heart valves. Some annuloplasty rings and sewing rings include fabric that is coated with an intrinsically conductive polymer. The coating can be formed over individual filaments or fibers, or on the fabric surface as a surface layer. One intrinsically conductive polymer is polypyrrole. The intrinsically conductive polymer can be doped to facilitate the intrinsic conductivity. Some devices have a polypyrrole surface layer doped with dialkyl-napthalene sulfonate. The intrinsically conductive polymer can be deposited on a fabric using in-situ polymerization of monomeric or oligomeric species, together with a dopant. Animal studies using implanted annuloplasty rings having an intrinsically conductive polymer coating have demonstrated a substantial reduction in pannus formation and inflammatory response.

A magnetic field device and method for inhibiting angiogenesis and retarding growth rates of cancerous tumors present in mammals. The apparatus includes a frame, and a wire consisting of electrically conducting material. The wire is wrapped around the frame to form a coil. A source of AC current is connected to a transformer to vary the AC voltage. The AC current is passed through a bridge rectifier and then to the coil of wire enabling a DC rectified wave magnetic field to be produced therefrom. The method employs the use of an apparatus which is capable of producing a magnetic field of a particular nature which has been proven in animal studies to affect angiogenesis and retard the growth rate of cancerous tumors.

The invention discloses a SgRNA (single chain guide ribonucleic acid) of the exon 2 of a specific targeted ApoE gene. The nucleotide sequence of the SgRNA is GCTTCTGGGATTACCTGCGC. The invention also discloses an ApoE-CRISPR / Cas9 carrier containing the SgRNA and application of the ApoE-CRISPR / Cas9 carrier to structuring ApoE gene knockout mammal models and to preparing ApoE gene knockout kits. TheApoE-CRISPR / Cas9 carrier structures the ApoE gene knockout mammal models; ApoE gene knockout can affect in vivo lipid metabolism of mammals and accelerate the pathogenic processes of lipid metabolismcorrelated diseases such as atherosclerosis to further accelerate the modeling process of corresponding mammal disease models and provide animal experiment basis for research on diseases such as atherosclerosis.

The present invention is generally related to the discovery of the use of a novel composition (Ri-Active™), containing a concentrate of the bioactives, micronutrients and antioxidants present in the unsaponifiable fraction of rice bran oil or rice germ oil, in the prevention and treatment of health disorders. The novel use of the by-products of rice bran oil or rice germ (and other vegetable oils) industries directly after purification and stabilization for therapeutic purposes is a unique and innovative approach that has been proved in the pilot study conducted by the current inventors. The current inventors have pioneered a new approach to prevent and treat health disorders such as cardiovascular diseases, hypercholesterolemia and diabetes which is both effective and inexpensive. The proprietary technology developed by the current inventors to produce Ri-Active™ from rice bran oil by-products or rice germ is very different from others who use these by-products to either isolate or purify individual micronutrients of value for use in other nutraceutical formulations. Most of the by-products of the edible oil refining industry are either discarded or sold at a throw away cost to the soap industry for their free fatty acid content. The novel technology and approach developed by the current inventors to utilize these low cost by-products from the edible oil refining industry and produce a highly effective therapeutic product has yielded a new and valuable use for these materials. This invention extends to the uses (therapeutic usefulness) and cost effectivity of similar whole extract concentrates of unsaponifiable micronutrients prepared from other vegetable oils rich in unsaponifiable fractions. The current discovery specifically covers the uses of Ri-Active™ (derived either from rice bran oil or rice germ oil), in preventing or treating cardiovascular disease, diabetes, hyperlipidemia, hypercholesterolemia and arteriosclerosis. Ri-Active™ contains many unsaponifiable bioactives and antioxidants of rice bran and rice germ in very high concentrations in a natural lipid matrix. These constituents in their natural lipid matrix act synergistically in the treatment of cardiovascular disease and other disorders and therefore the whole extract concentrate containing these constituents is far more efficacious than administering a mixture of procured ingredients in similar concentrations. The efficacy of this novel composition (Ri-Active™) in the treatment of cardiovascular disease risk factors has been proved in the pilot animal study conducted by the current inventors. Ri-Active™ has been tested to be safe, and highly effective in small doses.

The invention adopts a virtual medicine screening technology and a high-throughput screening technology, assesses the AChE inhibitory activity of more than ten thousand samples in a compound sample library and finds a batch of compounds with higher inhibitory activity by establishing a virtual acetylcholinesterase inhibitor screening method and an AChE activity detection method. Then according to the pathological features of senile dementia, the compounds with higher AChE inhibitory activity are subject to butyryl choline esterase inhibitory activity detection. Research results show that bimolecular 3-piperidyl-ethyl phenyl ketone not only has comparatively high AChE inhibitory activity, but also has very strong BuChE inhibitory activity; the results of animal experiments prove that the bimolecular 3-piperidyl-ethyl phenyl ketone can remarkably improve aphronesia caused by scopolamine and sodium nitrite and can enhance the ability of learning and memory.

The invention relates to a method for analyzing the stable isotope ratio of CO2 based on chromatography-mass spectrometry. The method comprises the following steps: firstly, building a mathematical model for the stable isotope ratio of CO2; secondly, purifying the carrier gas with purity lower than 10 <-5> percent with a purifier, so that the purity of the purified carrier gas is lower than 10 <-6> percent or 10 <-7> percent; thirdly, introducing the purified carrier gas in a gas chromatograph and a chromatographic column where a to-be-tested sample is placed, and then measuring the CO2 in the to-be-tested sample through a mass detector after adsorption and desorption, so as to obtain the mass number (44, 45, 46, 47, 48 and 49) of CO2 in the to-be-tested gas; and fourthly, performing substitution of the mass number (44, 45, 46, 47, 48 and 49) of CO2 in the to-be-tested gas in Table 2 to obtain 15 isotope ratios of CO2. The method achieves the purpose of subtly expressing the CO2 source by building the mathematical model, and can be applied to non-invasive detection in human health, human body medicine and planet and animal studies.